Speaker: Michael Leach, Therapeutic Area Lead, Drug Safety Research and Development, PfizerIn collaboration with: British Toxicology Society, the Society of Toxicologic Pathology, and the SOT Biotechnology Specialty Section.
There are currently many approved biologic products throughout the world, providing huge benefits across many therapeutic areas. At the present time, a number of biologics are coming off patent, which has opened the door to biosimilars. A biosimilar is a proposed biologic product which is highly similar to an already licensed/marketed biologic product, but because of the complexities of manufacturing biologics, it is not an exact copy. Proposed biosimilars can generally follow a tailored regulatory pathway with reduced development costs and time, with a goal of demonstrating no clinically meaningful differences based upon the totality of evidence. Global regulations vary in their requirements, and currently there is a lack of harmonization regarding exactly how much abbreviation of the nonclinical portion of biosimilar development is acceptable and appropriate. This presentation will review regulatory guidelines, discuss reasons why nonclinical in vivo studies are currently being conducted, discuss whether there has been value from those studies, and present a case for why nonclinical in vivo toxicity studies may not be necessary in support of many biosimilar development programs.
View Webinar Recording
Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and cohost societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.